Arrowstreet Capital’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.6M Buy
1,031,536
+375,892
+57% +$8.44M 0.01% 673
2026
Q2
$11.7M Buy
655,644
+445,051
+211% +$7.97M 0.01% 1024
2026
Q1
$3.77M Buy
+210,593
New +$4.6M ﹤0.01% 1244

Other funds holding CAI

Arrowstreet Capital's CAI Position: Q3 2026 in Review

Arrowstreet Capital increased its Caris Life Sciences (CAI) stake by 57% in Q3 2026, buying an estimated $8.44M and bringing the position to 1,031,536 shares worth $31.6M. The position accounts for 0.01% of the portfolio, ranked #673.

Arrowstreet Capital first reported a position in CAI in Q1 2026 and has held it in 3 quarters since. 330 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • Arrowstreet Capital held 1,031,536 shares of Caris Life Sciences worth $31.6M as of Q3 2026.
  • Arrowstreet Capital bought 375,892 Caris Life Sciences shares in Q3 2026, an estimated $8.44M.
  • Caris Life Sciences made up 0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #673 holding.
  • Arrowstreet Capital first reported a position in Caris Life Sciences in Q1 2026 and has held it in 3 quarters since.
  • 330 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.